Biapenem CAS No: 120410-24-4 Doripenem CAS No: 148016-81-3 Ertapenem CAS No: 153832-46-3 Imipenem CAS No: 74431-23-5 Meropenem CAS No: 96036-03-2 Panipenem CAS No: 87726-17-8 A new publication is out called “May 19, 2016 – Tackling Drug-Resistant Infections Globally: final report and recommendations” and it highlights the antibiotic-resistant infections which are being seen for the 1st[…]
Carbapenems API’s for Antibiotic Resistance
Antibiotic, Drug Research & Development API Tags: antibioticCDCUnited States May 27, 2016
Pleconaril is a Possible Therapy to Combat Enterovirus D68
Drug Research & Development API Tags: CDC Mar 04, 2015
The Enterovirus D68 has been in the headlines lately- and not for a positive reason. This rogue virus has parents and practitioners alarmed as it has progressed to severe illness in several children, leading to cases of possible paralysis. Treatment for this virulent strain of the Enterovirus is needed quickly, as some children have experienced[…]
Can Testosterone Be Used As a Preventative Treatment For Type 2 Diabetes In Men?
Anti-Diabetic, Drug Research & Development API, Hormonal Agent, OTC and Compounding Product, Patent Expiration 2017 Tags: AustraliaCDCtype 2 Diabetes Apr 22, 2013
Is Testosterone a potential preventative treatment for type 2 diabetes? Researchers at the University of Adelaide in Australia are hopeful that their latest research will be the kick-start for trials of testosterone as a preventative for this encompassing from of diabetes. Results from early stages of this current study, which were discussed at the 10th[…]
Entecavir Versus a Staggering Number of Hepatitis B Cases Worldwide
Antiviral, Patent Expiration 2015 Tags: CDCchronic hepatitis B Aug 03, 2012
Entecavir, CAS# 209216-23-9 may also be known by it’s brand name Baraclude. With the patent for Bristol-Myers Squibb’s Baraclude expiring on February 21, 2015, entecavir is on track to becoming a profitable generic product. Used to treat patients with chronic hepatitis B, entecavir is considered an antiviral medication. With a staggering 2 billion people around[…]
The Facts About Herpes and Treatment with Famciclovir
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2015 Tags: CDC Jul 18, 2012
As an effectual antiviral drug, Famciclovir, CAS number 104227-87-4, is a key treatment for infections caused by the herpes virus. Novartis holds the patent for Famvir, which is the brand name for famciclovir, but that is expiring on September 1, 2015. While famciclovir is not a cure for herpes, it will slow the growth and[…]
Pitavastatin Unique and Effectual for Treating Primary and Mixed Hyperlipidemia
Cardiovascular Agent, Drug Research & Development API, Patent Expiration 2015, Respiratory Tract Agent Tags: CDC Jun 26, 2012
Pitavastatin is often recognized by it’s brand name LOVALO, which is marketed by Kowa/Lilly. With the patent for LOVALO due to expire on May 19, 2015, this remarkable statin stands to create quite a stir as a generic product. Approved to treat both primary hyperlipidemia and mixed dyslipidemia, pitavastatin is unique as it offers an[…]
Report Shows Antibiotic Resistant Gonorrhea Increase
Antibiotic, Bulk Active Ingredient, Drug Research & Development API Tags: antibioticCDC Aug 03, 2011
Gonorrhea is a sexually transmitted disease (STD) caused by the bacterium Neisseria Gonorrhoeae. Gonorrhea is a very common infectious disease among the sexually active young adults and teens. The Center for Disease Control and Prevention (CDC) estimates that more than 700,000 persons in the U.S. acquire the infection yearly. Unlike HIV, exchange of body fluids[…]
